Pamrevlumab,一种抗结缔组织生

SCI

7Jan

Pamrevlumab,ananti-connectivetissuegrowthfactortherapy,foridiopathicpulmonaryfibrosis(PRAISE):aphase2,randomised,double-blind,placebo-controlledtrial（LancetRespMed,IF:22.9）

RicheldiL,FernándezPérezER,CostabelU,etal.Pamrevlumab,ananti-connectivetissuegrowthfactortherapy,foridiopathicpulmonaryfibrosis(PRAISE):aphase2,randomised,double-blind,placebo-controlledtrial.TheLancetRespiratoryMedicine;8:25-33.

Correspondenceto:ProfLucaRicheldi,UnitàOperativaComplessadiPneumologia,FondazionePoliclinicoUniversitarioA.GemelliIRCCS,UniversitàCattolicadelSacroCuore,Rome,Italyluca.richeldi

policlinicogemelli.it

Summary背景

BackgroundConnectivetissuegrowthfactor(CTGF)isasecretedglycoproteinthathasacentralroleintheprocessoffibrosis.Thisstudywasdesignedtoassessthesafety,tolerability,andefficacyofpamrevlumab(FG-),afullyre

转载请注明：http://www.beiermiantan.com/bemtjc/10143.html